How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?-Reference-Cited by-同舟云学术

How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?

Published:2020-01 Issue:1 Volume:4 Page:5-7
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatol Commun

Author:

Loglio Alessandro¹^ORCID,Lampertico Pietro¹^ORCID

Affiliation:

1. CRC “A.M. and A. Migliavacca” Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Università degli Studi di Milano Milan Italy

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1476

Reference9 articles.

1. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B

2. Durability of spontaneous and treatment‐related loss of hepatitis B s antigen;Alaward AS;Clin Gastroenterol Hepatol,2019

3. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients

4. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

5. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured);Clinical Pharmacology in Drug Development;2024-09-13

2. Unmet needs in the clinical management of chronic hepatitis B infection;Journal of the Formosan Medical Association;2024-08

3. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B;Journal of Hepatology;2024-08

4. Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies;Infectious Diseases and Therapy;2024-05-25

5. B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection;Advances in Therapy;2023-07-01